Cyclooxygenase Inhibitors Down Regulate P-glycoprotein in Human Colorectal Caco-2 Cell Line
- First Online:
- 463 Downloads
Elevated expression of the ABC transporters P-glycoprotein (P-gp), and breast cancer resistance protein (BCRP) seems to correlate with multidrug resistance of cancer cells. In this study we investigated the effect of COX inhibitors in modulating P-gp and BCRP expression and P-gp activity in Caco-2 cells.
mRNA and protein expression of MDR1 and BCRP were evaluated by real time PCR and western blot respectively. The activity of P-gp was measured by intracellular accumulation of rhodamine123 or 3H-Digoxin.
The chronic exposure of Caco-2 to indomethacin heptyl ester (indo HE) (0.4 μM) or nimesulide (10 μM) (selective COX-2 inhibitors) and naproxen (6 μM) (non selective inhibitor COX-1/COX-2) significantly decreased the expression and activity of P-gp. In contrast, the acute treatment by nimesulide and naproxen did not modify these parameters while indo HE treatment (48–72 h) caused a protein decrease and a functional inhibition of P-gp. Unexpectedly, the short-term treatment with naproxen induced an important increase of BCRP expression, but this induction was lost after long-term treatment. No modification of BCRP expression was observed after indo HE or nimesulide treatment.
Our observations suggest a possible down regulation of P-gp by COX inhibitors, which may enhance the accumulation of chemotherapy agents.
KEY WORDSBCRP Caco-2 COX-2 inhibitor MDR1 P-gp
- 5.G. P. O'Neilland, and A. W. Ford-Hutchinson. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett. 330:156–60 (1993).Google Scholar
- 6.C. C. Chan, S. Boyce, C. Brideau, A. W. Ford-Hutchinson, R. Gordon, D. Guay, R. G. Hill, C. S. Li, J. Mancini, M. Penneton et al. Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J. Pharmacol. Exp. Ther. 274:1531–1537 (1995).PubMedGoogle Scholar
- 9.C. E. Trebino, J. L. Stock, C. P. Gibbons, B. M. Naiman, T. S. Wachtmann, J. P. Umland, K. Pandher, J. M. Lapointe, S. Saha, M. L. Roach, D. Carter, N. A. Thomas, B. A. Durtschi, J. D. McNeish, J. E. Hambor, P. J. Jakobsson, T. J. Carty, J. R. Perez, and L. P. Audoly. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc. Natl. Acad. Sci. USA. 100:9044–9049 (2003).PubMedCrossRefGoogle Scholar
- 12.I. I. Singer II, D. W. Kawka, S. Schloemann, T. Tessner, T. Riehl, and W. F. Stenson. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115:297–306 (1998).Google Scholar
- 16.N. Arber, C. J. Eagle, J. Spicak, I. Racz, P. Dite, J. Hajer, M. Zavoral, M. J. Lechuga, P. Gerletti, J. Tang, R. B. Rosenstein, K. Macdonald, P. Bhadra, R. Fowler, J. Wittes, A. G. Zauber, S. D. Solomon, and B. Levin. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355:885–95 (2006).PubMedCrossRefGoogle Scholar
- 17.Y. Goldberg, Nassif, II, A. Pittas, L. L. Tsai, B. D. Dynlacht, B. Rigas, and S. J. Shiff. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 12:893–901 (1996).Google Scholar
- 18.J. Shao, T. Fujiwara, Y. Kadowaki, T. Fukazawa, T. Waku, T. Itoshima, T. Yamatsuji, M. Nishizaki, J. A. Roth, and N. Tanaka. Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene. 19:726–36 (2000).PubMedCrossRefGoogle Scholar
- 19.S. Hashitani, M. Urade, N. Nishimura, T. Maeda, K. Takaoka, K. Noguchi, and K. Sakurai. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int. J. Oncol. 23:665–672 (2003).PubMedGoogle Scholar
- 23.M. C. Zatelli, A. Luchin, D. Piccin, F. Tagliati, A. Bottoni, C. Vignali, M. Bondanelli, and E. C. degli Uberti. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 90:5754–5760 (2005).PubMedCrossRefGoogle Scholar
- 27.S. Siissalo, L. Laitinen, M. Koljonen, K. S. Vellonen, H. Kortejarvi, A. Urtti, J. Hirvonen, and A. M. Kaukonen. Effect of cell differentiation and passage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur. J. Pharm. Biopharm. 67:548–54 (2007).PubMedCrossRefGoogle Scholar
- 38.U. Puhlmann, C. Ziemann, G. Ruedell, H. Vorwerk, D. Schaefer, C. Langebrake, P. Schuermann, U. Creutzig, and D. Reinhardt. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J. Pharmacol. Exp. Ther. 312:346–354 (2005).PubMedCrossRefGoogle Scholar